Samir Zaidi, MD, PhD
Assistant Professor of Internal Medicine (Medical Oncology/Hematology)Cards
About
Research
Publications
2025
Patterns of intra- and inter-tumor phenotypic heterogeneity in lethal prostate cancer
Roudier M, Gulati R, Sayar E, Patel R, Tratt M, Richards H, Cejas P, Gomez M, Qiu X, Xie Y, Hanratty B, Zaidi S, Zhao J, Adil M, Mittal C, Zhao Y, Dumpit R, Coleman I, Low J, Persse T, Galipeau P, Lee J, Tretiakova M, Chambers M, Vakar-Lopez F, True L, Perrone M, Lam H, Kollath L, Ding C, Harmon S, Cheng H, Yu E, Montgomery R, Hawley J, Lin D, Corey E, Schweizer M, Setty M, Ha G, Sawyers C, Morrissey C, Long H, Nelson P, Haffner M. Patterns of intra- and inter-tumor phenotypic heterogeneity in lethal prostate cancer. Journal Of Clinical Investigation 2025, 135: e186599. PMID: 40493417, PMCID: PMC12321404, DOI: 10.1172/jci186599.Peer-Reviewed Original ResearchMetastatic prostate cancerLethal prostate cancerProstate cancerPhenotypic heterogeneityMetastatic prostate cancer patientsMolecularly heterogeneous diseaseTumor cell populationIntra-tumor heterogeneityCellular proliferation rateMetastatic sitesSingle-cell sequencing studiesMolecular subtypesClinical featuresTumor heterogeneityTumor phenotypeTumor samplesHeterogeneous diseaseClinical managementAnatomical sitesTherapeutic approachesSubtype heterogeneityPatientsTissue-basedCell populationsProliferation rate
2024
The neuroendocrine transition in prostate cancer is dynamic and dependent on ASCL1
Romero R, Chu T, González Robles T, Smith P, Xie Y, Kaur H, Yoder S, Zhao H, Mao C, Kang W, Pulina M, Lawrence K, Gopalan A, Zaidi S, Yoo K, Choi J, Fan N, Gerstner O, Karthaus W, DeStanchina E, Ruggles K, Westcott P, Chaligné R, Pe’er D, Sawyers C. The neuroendocrine transition in prostate cancer is dynamic and dependent on ASCL1. Nature Cancer 2024, 5: 1641-1659. PMID: 39394434, PMCID: PMC11584404, DOI: 10.1038/s43018-024-00838-6.Peer-Reviewed Original ResearchConceptsNeuroendocrine prostate cancerProstate cancerLineage plasticityAndrogen receptor signaling inhibitorsCancer progressionMouse prostate organoidsProstate cancer progressionRB1 deletionProstate organoidsMultiplex immunofluorescenceIn vivo platformTransient regressionDriver mutationsLuminal cellsSignaling InhibitorsAscl1Neuroendocrine transitionLineage transformationOrganoid culturesCancerTherapy outcomeProstateAdenocarcinomaTherapy timeIn vivo microenvironmentEffect of CDC7 inhibition and MYC degradation on neuroendocrine transformation in the lung and prostate cancer.
Quintanal-Villalonga A, Kawasaki K, Redin E, Rakhade S, Durani V, Sabet A, Karthaus W, Zaidi S, Zhan Y, Manoj P, Sridhar H, Zhong H, Mello B, Ciampricotti M, Bhanot U, Haffner M, Socci N, Yu H, Chan J, Rudin C. Effect of CDC7 inhibition and MYC degradation on neuroendocrine transformation in the lung and prostate cancer. Journal Of Clinical Oncology 2024, 42: e20105-e20105. DOI: 10.1200/jco.2024.42.16_suppl.e20105.Peer-Reviewed Original ResearchRisk of transformationNE transformationProstatic adenocarcinomaTherapeutic vulnerabilitiesMYC degradationPhase II clinical trialLung tumor modelDelays tumor relapseII clinical trialsTherapy in vivoIn vivo prostateMechanisms of resistanceMYC isoformsNE phenotypeTumor relapseUntreated tumorsNeuroendocrine transformationProstate cancerStemness transcription factorsPotential therapeutic targetTargeted therapyPoor prognosisTumor modelProstateTumor populationCEACAM5-Targeted Immuno-PET in Androgen Receptor–Negative Prostate Cancer
Imberti C, De Gregorio R, Korsen J, Hoang T, Khitrov S, Kalidindi T, Nandakumar S, Park J, Zaidi S, Pillarsetty N, Lewis J. CEACAM5-Targeted Immuno-PET in Androgen Receptor–Negative Prostate Cancer. Journal Of Nuclear Medicine 2024, 65: 1043-1050. PMID: 38782457, PMCID: PMC11218725, DOI: 10.2967/jnumed.123.267107.Peer-Reviewed Original ResearchConceptsNeuroendocrine prostate cancerCarcinoembryonic antigen-related cell adhesion molecule 5CEACAM5 expressionProstate cancerAggressive neuroendocrine prostate cancerAndrogen receptor (AR)-negativeEx vivo organ distributionXenograft prostate cancer modelsProstate cancer cell linesProstate cancer modelCell line LNCaP.Immuno-PET imagingCell line PC3Prostate cancer hallmarksCancer cell linesCancer modelsRadiolabeled antibodiesImmuno-PETSurface antigensProstatePET imagingCancerCancer hallmarksWestern blottingCell linesUnderstanding osteokine biology
Zaidi M, Zaidi S, Yuen T. Understanding osteokine biology. Cell Metabolism 2024, 36: 888-890. PMID: 38718755, PMCID: PMC11705590, DOI: 10.1016/j.cmet.2024.04.008.Peer-Reviewed Original Research
2023
2233MO CDC7 inhibition constrains lineage plasticity and prevents resistance and neuroendocrine transformation in the lung and prostate
Quintanal-Villalonga Á, Zaidi S, Karthaus W, Zhan Y, Shafer M, Qiu J, de Stanchina E, Haffner M, Sawyers C, Rudin C. 2233MO CDC7 inhibition constrains lineage plasticity and prevents resistance and neuroendocrine transformation in the lung and prostate. Annals Of Oncology 2023, 34: s1150. DOI: 10.1016/j.annonc.2023.09.1261.Peer-Reviewed Original ResearchExportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers
Quintanal-Villalonga A, Durani V, Sabet A, Redin E, Kawasaki K, Shafer M, Karthaus W, Zaidi S, Zhan Y, Manoj P, Sridhar H, Shah N, Chow A, Bhanot U, Linkov I, Asher M, Yu H, Qiu J, de Stanchina E, Patel R, Morrissey C, Haffner M, Koche R, Sawyers C, Rudin C. Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers. Science Translational Medicine 2023, 15: eadf7006. PMID: 37531417, PMCID: PMC10777207, DOI: 10.1126/scitranslmed.adf7006.Peer-Reviewed Original ResearchConceptsPatient-derived xenograftsProstatic adenocarcinomaNE transformationXenograft modelExportin 1Associated with poor prognosisProstate adenocarcinoma cell lineInactivation of TP53Adenocarcinoma xenograft modelEctopic SOX2 expressionEGFR inhibitor osimertinibAdenocarcinoma cell lineNE phenotypeNeuroendocrine transformationSelinexor treatmentStandard cytotoxicsProstate cancerLineage plasticityPotential therapeutic targetNE featuresPoor prognosisProstateSOX2 expressionAdenocarcinomaLungEffect of Janus kinase (JAK) signaling inhibition on lineage plasticity and drug sensitivity in castrate resistant prostate cancer.
Zaidi S, Chan J, Love J, Zhao J, Setty M, Lawrence K, Gopalan A, Goodrich D, Morris M, Chen Y, Karthaus W, Pe'er D, Sawyers C. Effect of Janus kinase (JAK) signaling inhibition on lineage plasticity and drug sensitivity in castrate resistant prostate cancer. Journal Of Clinical Oncology 2023, 41: 227-227. DOI: 10.1200/jco.2023.41.6_suppl.227.Peer-Reviewed Original ResearchAndrogen receptor signaling inhibitorsFDA-approved inhibitorFibroblast growth factor receptorLineage plasticityProstate cancerAndrogen receptorInhibitors of JAK/STATSuccess of targeted cancer therapyCastration resistant prostate cancerSignaling InhibitorsLoss of tumor suppressor genesCases of prostate cancerFibroblast growth factor receptor signaling pathwayJanus kinaseSingle cell RNA analysisRadiologically guided biopsyResistant prostate cancerEffects of Janus kinaseIncreased androgen receptorTumor-derived organoidsGenetic editing toolsResistance to therapySingle cell RNA sequencingGrowth factor receptorTumor suppressor gene
2022
5 Oral Lineage plasticity in prostate cancer depends on FGFR and JAK/STAT inflammatory signaling
Chan J, Zaidi S, Love J, Zhao J, Setty M, Wadosky K, Gopalan A, Choo Z, Persad S, Chaudhary O, Xu T, Masilionis I, Morris M, Mazutis L, Chaligne R, Chen Y, Goodrich D, Karthaus W, Pe’er D, Sawyers C. 5 Oral Lineage plasticity in prostate cancer depends on FGFR and JAK/STAT inflammatory signaling. European Journal Of Cancer 2022, 174: s4-s5. DOI: 10.1016/s0959-8049(22)00818-8.Peer-Reviewed Original ResearchLineage plasticity in prostate cancer depends on JAK/STAT inflammatory signaling
Chan J, Zaidi S, Love J, Zhao J, Setty M, Wadosky K, Gopalan A, Choo Z, Persad S, Choi J, LaClair J, Lawrence K, Chaudhary O, Xu T, Masilionis I, Linkov I, Wang S, Lee C, Barlas A, Morris M, Mazutis L, Chaligne R, Chen Y, Goodrich D, Karthaus W, Pe'er D, Sawyers C. Lineage plasticity in prostate cancer depends on JAK/STAT inflammatory signaling. Science 2022, 377: 1180-1191. PMID: 35981096, PMCID: PMC9653178, DOI: 10.1126/science.abn0478.Peer-Reviewed Original ResearchConceptsFibroblast growth factor receptorProstate cancerLineage plasticityJanus kinaseGenetically engineered mouse modelsCastration-resistant diseaseFibroblast growth factor receptor signalingTumor cell statesGrowth factor receptorSingle-cell analysisMetastatic diseaseStratify patientsIncreased JAK/STATAntiandrogen resistanceEpithelial populationsDrug resistanceFactor receptorClinical trialsInhibitor treatmentMouse modelInflammatory signalingGene expressionCell statesMurine organoidsMolecular mechanisms
Academic Achievements & Community Involvement
Get In Touch
Contacts
Email
Mailing Addresses
Yale Medicine
333 Cedar Street
New Haven, CT 06520
United States
Center of Molecular and Cellular Oncology
300 George Street
New Haven, CT 06520
United States